Novalis Biotech
Overview
Novalis Biotech is a Belgium-based early-stage venture capital firm that invests in enabling technologies within the life sciences, including genomics, bioinformatics, diagnostics, and digital health.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Trince | Dec 2021 | Series A | Lead |
| Grapheal | Feb 2021 | Seed | Co-investor |
| Rarity Bioscience | Jun 2024 | VC Round | Co-investor |
| Enzyre | Nov 2022 | Series A | Co-investor |
| BioLizard | Sep 2020 | Seed | Co-investor |
For institutional investors. Book with your work email.
Key People
Jan Van den Berghe
Co-Founder
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Novalis Biotech based?
Novalis Biotech is headquartered in Belgium.
When was Novalis Biotech founded?
Novalis Biotech was founded in 2018.
How many portfolio companies does Novalis Biotech have?
Novalis Biotech has 10 portfolio companies in Caplight's dataset.
What are some companies in Novalis Biotech's portfolio?
Portfolio companies visible on Caplight include Trince, Grapheal, Rarity Bioscience, Enzyre, BioLizard.
What was Novalis Biotech's most recent investment shown here?
Novalis Biotech's most recent investment in this portfolio sample was in Rarity Bioscience in 2024.
What sectors does Novalis Biotech focus on?
Novalis Biotech focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure.
What company stages does Novalis Biotech focus on?
Novalis Biotech typically invests at the Early stage.
What is Novalis Biotech's AUM?
Novalis Biotech's assets under management are estimated between $29.0M and $35.4M.